Ultima Genomics Adds Former Thermo Fisher Exec Mark Stevenson to Board of Directors
Ultima Genomics, a developer of an innovative new ultra-high throughput sequencing architecture, today announced that Mark Stevenson will join its Board of Directors. Mark brings more than 30 years of experience and leadership in the Life Sciences sector, most recently serving as Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific, where he was responsible for the portfolio of life science, analytical and diagnostic businesses as well as the innovation and digital strategy.
Hartwig and Ultima Genomics Collaborate to Reduce Costs for Whole Genome Cancer Profiling, Minimal Residual Disease Testing and Generating Genetic Data at Scale
Hartwig Medical Foundation, a pioneer in deploying complete genomic profiling to improve oncology outcomes, and Ultima Genomics, a developer of a revolutionary new ultra-high throughput next-generation sequencing (NGS) architecture, today announced the deployment of Ultima’s UG 100 sequencing system and its proprietary ppmSeq technology for improving precision oncology testing and research. This collaboration aims to reduce test costs and make complete genome-based cancer diagnostics accessible for more patients to have better informed cancer treatment. In parallel, platform strengths will be explored for minimal residual disease detection in blood of cancer patients with a one-size-fits-all solution that builds on pre-existing complete tumor profile information.
Ultima Announces UG 100™ and Reveals Disruptive Cost and Accuracy Profile to Enable the Era of the $100 Genome and Beyond
Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput sequencing architecture, today announced the full commercial availability of the UG 100TM sequencer. The UG 100TM system, Ultima’s first commercial product, leverages Ultima’s unique sequencing architecture featuring an open silicon wafer substrate to replace the traditional flow cells and enable the $100 genome and beyond.
Ultima Genomics Announces End of Early Access and Upcoming Launch of UG 100™
Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput sequencing architecture, today announced the launch and full commercial availability of the UG 100™ at the upcoming Advances in Genome Biology and Technology (AGBT) conference on February 5, 2024.
Quest Diagnostics and Ultima Collaborate to Scale Ultima’s Technology in Fast-Growing Minimal Residual Disease and Whole Genome Sequencing
Ultima Genomics, a developer of a revolutionary new ultra-high throughput sequencing architecture, and Quest Diagnostics (
NYSEDGX), the nation’s leading provider of diagnostic information services, today announced a collaboration involving Ultima’s next generation sequencing (NGS) technology in oncology and other clinical areas.
Ultima Genomics to Present at ASHG and Provide Updated Reference Data Set
Ultima Genomics, Inc., a developer of an innovative new ultra-high throughput sequencing architecture, will present, along with several early access customers, new data across a range of different applications at the American Society of Human Genetics (ASHG) annual meeting on Nov. 1-5, 2023, in Washington D.C.
